BTIG analyst Ryan Zimmerman lowered the firm’s price target on Stryker to $360 from $372 but keeps a Buy rating on the shares. The company continues to execute to the level investors expect with near double-digit organic growth for multiple years in a row, and the management expects healthy procedure dynamics sustaining in 2H24 coupled with new product launches, but the big question that’s left is whether Stryker can drive 100bps of margin expansion in FY24 and then again in FY25, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- SYK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- SYK, ISRG, DXCM: Which “Strong Buy” Healthcare Stock Is the Best Bet?
- Stryker price target raised to $350 from $345 at Morgan Stanley
- Stryker price target raised to $372 from $369 at BTIG
- Stryker price target lowered to $365 from $370 at Evercore ISI